The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients DOI Creative Commons

Yibin Zhang,

Xiao-xing Liao,

Jialu Xu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2783 - 2783

Published: Dec. 6, 2024

Type 2 diabetes mellitus (T2DM), accounting for the majority of prevalence, is associated with an increased risk cognition decline and deterioration function in diabetic patients. The sodium–glucose cotransporter (SGLT2), located renal proximal tubule, plays a role urine glucose reabsorption. SGLT2 inhibitors (SGLT2i), have shown potential benefits beyond cardiac improvement preventing treating cognitive impairment (CI), including mild impairment, Alzheimer’s disease vascular dementia T2DM Studies suggest that SGLT2i may ameliorate CI through metabolism pathways, inflammation, oxidative stress, neurotrophic factors AChE inhibition. Clinical trials meta-analyses reported significant insignificant results. Given their effects, offer unique protection against CI. This review compiles mechanisms clinical evidence, emphasizing need future analysis, evaluation, to verify recommend optimal selection dosage specific

Language: Английский

Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges DOI

Jacky Tran,

Sneh Parekh,

Julia Rockcole

et al.

Life Sciences, Journal Year: 2024, Volume and Issue: 355, P. 123001 - 123001

Published: Aug. 22, 2024

Language: Английский

Citations

8
A novel electrochemical strategy for rapid and sensitive α-Glucosidase activity detection and inhibitor discovery based on distinct oxidation potentials of substrate and product DOI
Jiǎ Hóng,

Jiaqi Cao,

Xiyu Chen

et al.

Microchemical Journal, Journal Year: 2025, Volume and Issue: unknown, P. 113678 - 113678

Published: April 1, 2025

Language: Английский

Citations

0
The Role and Mechanism of Metformin in the Treatment of Nervous System Diseases DOI Creative Commons
Hui Li, Ruhui Liu, Junyan Liu

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(12), P. 1579 - 1579

Published: Dec. 10, 2024

Nervous system diseases represent a significant global burden, affecting approximately 16% of the world’s population and leading to disability mortality. These conditions, encompassing both central nervous (CNS) peripheral (PNS) disorders, have substantial social economic impacts. Metformin, guanidine derivative derived from plant source, exhibits therapeutic properties in various health conditions such as cancer, aging, immune-related polycystic ovary syndrome, cardiovascular ailments, more. Recent studies highlight metformin’s ability cross blood–brain barrier, stimulate neurogenesis, provide beneficial effects specific neurological disorders through diverse mechanisms. This review discusses advancements research on role mechanisms treating within systems, aiming facilitate further investigation, utilization, clinical application metformin neurology.

Language: Английский

Citations

2
Ketogenic interventions restore cognition and modulate peripheral metabolic dysfunctions in Alzheimer's disease mouse models DOI Creative Commons

Paule E. H. M’Bra,

Laura K. Hamilton, Gaël Moquin‐Beaudry

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 10, 2024

Summary Lifestyle factors modulate dementia risk. We investigated mechanisms of risk reduction by emerging dietary ketogenic interventions. show that distinct interventions, a medium-chain triglycerides (MCT)-enriched diet and carbohydrate-free, high-fat (CFHF), improve cognition dendritic spine density memory-associated hippocampal neurons in two mouse models Alzheimer’s disease (AD). Only the CFHF drove increased circulating ketones, suggesting underlying mechanisms. AD mice exhibited baseline diet-induced susceptibility to peripheral metabolic disturbances were improved MCT exacerbated diets. Prominent AD-associated dysregulation liver transcriptome was largely restored both but also downregulated lipogenic enzymes did not trigger CFHF-like inflammatory signature. Novel AD- plasmatic changes hormones lipid species identified. Thus, different interventions yield cognitive benefits while showing intervention-specific modulation defects, with implications for design therapeutic strategies.

Language: Английский

Citations

0
Bayesian Probability Intelligent Forecasting Model Based on Rainfall during Flood Season DOI
Peng Zeng, Weidong Zhang,

Yangjun Zhou

et al.

Published: May 31, 2024

Language: Английский

Citations

0
The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients DOI Creative Commons

Yibin Zhang,

Xiao-xing Liao,

Jialu Xu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2783 - 2783

Published: Dec. 6, 2024

Type 2 diabetes mellitus (T2DM), accounting for the majority of prevalence, is associated with an increased risk cognition decline and deterioration function in diabetic patients. The sodium–glucose cotransporter (SGLT2), located renal proximal tubule, plays a role urine glucose reabsorption. SGLT2 inhibitors (SGLT2i), have shown potential benefits beyond cardiac improvement preventing treating cognitive impairment (CI), including mild impairment, Alzheimer’s disease vascular dementia T2DM Studies suggest that SGLT2i may ameliorate CI through metabolism pathways, inflammation, oxidative stress, neurotrophic factors AChE inhibition. Clinical trials meta-analyses reported significant insignificant results. Given their effects, offer unique protection against CI. This review compiles mechanisms clinical evidence, emphasizing need future analysis, evaluation, to verify recommend optimal selection dosage specific

Language: Английский

Citations

0